Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Spironolactone pharmacokinetics and actions in the dog: Influence on the potential spironolactone-digoxin interaction

Thesis/Dissertation ·
OSTI ID:5547717
This study was designed to determine if administration of spironolactone to achieve steady-state concentrations to dogs at steady-state digoxin concentration resulted in an increased serum digoxin concentration in dogs. Serum digoxin concentration and AcS tolerance were measured in dogs at steady-state spironolactone-digoxin concentration to determine if an increase in serum digoxin concentration resulted from spironolactone administration and if this resulted in increased cardiac effects of digoxin. To determine if a spironolactone-digoxin interaction occurred at the canine myocardial digitalis receptor in vitro, the effects of spironolactone and its metabolites on Na{sup +},K{sup +}-ATPase activity and ({sup 3}H)ouabain binding were studied. Spironolactone, canrenone, or K{sup +} canrenoate did not inhibit canine myocardial K{sup +}-dependent MFPase activity or the concentration-response curve for digoxin inhibition of K{sup +}-dependent MFPase. In contrast, 0.1 mM spironolactone or canrenone competitively antagonized ({sup 3}H)ouabain binding to canine myocardium. Neither 0.24 {mu}M spironolactone, 0.59 {mu}M canrenone, or 1.27 {mu}M 7{alpha}-thiomethylspirolactone, concentrations of spironolactone and its metabolites found after a therapeutic dose of spironolactone in man, altered ({sup 3}H)ouabain binding to canine myocardium.
Research Organization:
Medical Coll. of Ohio, Toledo, OH (USA)
OSTI ID:
5547717
Country of Publication:
United States
Language:
English